Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 27.
doi: 10.1111/imj.70179. Online ahead of print.

Safety, tolerability and efficacy of the use of tixagevimab/cilgavimab as pre-exposure COVID-19 prophylaxis in kidney and simultaneous pancreas kidney transplant recipients

Wai H Lim  1   2   3 , Jiayue Wang  4 , Helen Pilmore  5   6 , Stella McGinn  7 , Anoushka Krishnan  8 , Armando Teixeira-Pinto  4   9 , Anh Kieu  9 , Owen Ng  9 , Germaine Wong  4   9   10
Affiliations

Safety, tolerability and efficacy of the use of tixagevimab/cilgavimab as pre-exposure COVID-19 prophylaxis in kidney and simultaneous pancreas kidney transplant recipients

Wai H Lim et al. Intern Med J. .

Abstract

The COVID-19 pandemic resulted in high mortality rates in immunocompromised people, especially those who have received solid organ transplants. In this cohort of 540 transplant recipients who received tixagevimab/cilgavimab (Evusheld®) in Australia and New Zealand between January 2022 and January 2023, 11 (2%) Evusheld®-treated recipients experienced moderate to severe COVID-19 infection, with two deaths from COVID-19 pneumonitis. Less than 0.5% experienced adverse events from Evusheld®. Prophylactic monoclonal antibody therapy may be considered an important adjunct to vaccination among immunocompromised patients to prevent severe infection during future viral outbreaks.

Keywords: COVID‐19; Evusheld®; monoclonal antibody; prophylaxis; tixagevimab/cilgavimab; transplant.

PubMed Disclaimer

References

    1. Li J, Huang DQ, Zou B, Yang H, Hui WZ, Rui F et al. Epidemiology of COVID‐19: a systematic review and meta‐analysis of clinical characteristics, risk factors, and outcomes. J Med Virol 2021; 93: 1449–1458.
    1. The Lancet Respiratory M. COVID‐19 heralds a new era for chronic diseases in primary care. Lancet Respir Med 2020; 8: 647.
    1. Fang M, Wang D, Tang O, Selvin E. Prevalence of chronic disease in laboratory‐confirmed COVID‐19 cases and U.S. adults (2017–2018). Diabetes Care 2020; 43: e127–e128.
    1. Valeri AM, Robbins‐Juarez SY, Stevens JS, Ahn W, Rao MK, Radhakrishnan J et al. Presentation and outcomes of patients with ESKD and COVID‐19. J Am Soc Nephrol 2020; 31: 1409–1415.
    1. Hilbrands LB, Duivenvoorden R, Vart P, Franssen CFM, Hemmelder MH, Jager KJ et al. COVID‐19‐related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration. Nephrol. Dial. Transpl: Off Publ Eur Dial Transpl Assoc ‐ Eur Ren Assoc 2020; 35: 1973–1983.

Grants and funding

LinkOut - more resources